<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565134</url>
  </required_header>
  <id_info>
    <org_study_id>AP-TRPV1_PII-02</org_study_id>
    <nct_id>NCT02565134</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus</brief_title>
  <official_title>Multi Center, Double-blind, Randomized, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Antipruritic Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Skin Pruritus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a Phase II, multi center, randomized, double-blind, placebo-controlled study in
      male and female subjects, aged â‰¥ 19 years with skin pruritus. All subjects will receive BID
      topical applications of PAC-14028 cream or vehicle for up to 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intensity of pruritus as measured by 10 cm VAS</measure>
    <time_frame>Week 4 from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment success rate (A decrease in VAS by 2 or more is judged as a success)</measure>
    <time_frame>Week 4 from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Overall Dry Skin (ODS) score</measure>
    <time_frame>Week 4 from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Transepidermal Water Loss (TEWL)</measure>
    <time_frame>Week 4 from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">296</enrollment>
  <condition>Skin Pruritus</condition>
  <arm_group>
    <arm_group_label>PAC-14028 cream 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 0.1%, Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 0.3%, Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 cream 1.0%, Twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-14028 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PAC-14028 cream vehicle, Twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 0.1%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 0.3%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream 1.0%</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC-14028 cream vehicle</intervention_name>
    <description>Topical application</description>
    <arm_group_label>PAC-14028 cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 19 - 70 years

          -  Patients who have eczema or xerosis cutis at the area where investigational product is
             applied (arm or leg)

          -  Patients whose result of the pruritus test (Visual Analogue Scale, VAS) at Visit 1 and
             2 is 5 or more

          -  Patients whose overall dry skin score of the area where investigational product is
             applied at Visit 1 and 2 is 2 points or more

        Exclusion Criteria:

          -  Patients with pruritus caused by other medical, psychotic and nervous causes other
             than the skin disease

          -  Patients with such skin diseases as malignant tumor or chronic urticaria among
             patients with skin diseases

          -  Patients with simple pruritus caused by such allergic material as scabies, and insect
             bite wound

          -  Patients with the symptom of systemic infection at the time of the participation in
             the clinical study

          -  Patients with a history of taking topical treatment drug, topical steroid agent or
             antibiotics for the treatment of pruritus within 2 weeks

          -  Patients with a history of taking oral steroid agent within 4 weeks

          -  Patients with a history of taking a physical treatment for the treatment of pruritus
             including phototherapy within 4 weeks

          -  Pregnant or breast-feeding women

          -  Women at a childbearing age who has childbearing potential or has a plan to get
             pregnant during the clinical study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miyoung Park, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Amorepacific R&amp;D Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

